Minocycline (hydrochloride) (Standard)

Minocycline (hydrochloride) (Standard) is the analytical standard of Minocycline (hydrochloride) . This product is intended for research and analytical applications. Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF) -1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect[1][2][3][4][5][6][7].

Product Specifications

CAS Number

[13614-98-7]

UNSPSC

12352005

Hazard Statement

H315, H319, H335, H351, H361

Target

Antibiotic; Apoptosis; Bacterial; Calcium Channel; HIF/HIF Prolyl-Hydroxylase; MDM-2/p53; Potassium Channel; Reference Standards

Type

Reference Standards

Related Pathways

Anti-infection; Apoptosis; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; Others

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/minocycline-hydrochloride-standard.html

Purity

99.50

Smiles

OC1=C(C(N)=O)C([C@@]2(O)C(O)=C3C(C4=C(O)C=CC(N(C)C)=C4C[C@@]3([H])C[C@@]2([H])[C@@H]1N(C)C)=O)=O.Cl

Molecular Formula

C23H28ClN3O7

Molecular Weight

493.94

Precautions

H315, H319, H335, H351, H361

References & Citations

[1]Xu L, et al. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol. 2004 Apr 26;4:7.|[2]Zhang L, et al. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30 (8) :1381-93. |[3]Pourgholami MH, et al. Minocycline inhibits growth of epithelial ovarian cancer. Gynecol Oncol. 2012 May;125 (2) :433-40.|[4]Molina-Hernández M, et al. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32 (2) :380-6.|[5]Ritchie DJ, et al. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014 Dec 1;59 Suppl 6:S374-80.|[6]Ataie-Kachoie P, et al. Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies. Am J Cancer Res. 2015 Jan 15;5 (2) :575-88.|[7]Hu X, Wu B, Wang X, Xu C, He B, Cui B, Lu Z, Jiang H. Minocycline attenuates ischemia-induced ventricular arrhythmias in rats. Eur J Pharmacol. 2011 Mar 11;654 (3) :274-9.